1 Min Read
Sept 11 (Reuters) - Diamedica Therapeutics Inc
* Diamedica announces the initiation of phase 2 trial evaluating DM199 (recombinant human Klk1) in patients with acute ischemic stroke Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.